Half of the poulation facing this illness require hospitalisation and if not treated with effective antibiotics, it can cause sepsis and death, researchers said.
In the study led by researchers at University of California, Los Angeles (UCLA) based on data from 10 large hospital emergency departments around the US, almost 12 per cent of people diagnosed with pyelonephritis had infections resistant to the standard class of antibiotic used in treatment – fluoroquinolone.
That is up from 4 per cent in a similar study conducted a decade ago, researchers said. In some cities, and among some people with certain risk factors such as international travel or recent hospitalisation or treatment with an antibiotic fluoroquinolone resistance rates exceeded 20 per cent.
Currently, there are only a few intravenous antibiotic options to treat ESBL-related infections, and no oral antibiotics that are consistently effective, they said. “This is a very real example of the threat posed by the emergence of new antibiotic-resistant strains of bacteria, which greatly complicates treatment of infection,” said Dr David Talan, the study’s lead author.
The study included 453 people diagnosed with kidney infection. The participants were diagnosed between July 2013 and December 2014 in 10 emergency departments at large hospitals. Talan and his colleagues recommended the development of new medications and new guidelines calling for treatment with different types and combinations of antibiotics.